Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis?

Peritoneal Dialysis International

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Bozkurt, Devrim ^a   Sipahi, Savas ^a   Cetin, Pinar ^a   Hur, Ender ^a   Özdemir, Özden ^a   Ertilav, Muhittin ^a   Sen, Sait ^a   Duman, Soner ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Encapsulating peritoneal sclerosis; Immunosuppressive treatment; Peritoneal morphology

Indexed keywords

ALCOHOL; AZATHIOPRINE; CHLORHEXIDINE GLUCONATE; CYCLOSPORIN A; DRINKING WATER; METHYLPREDNISOLONE; SODIUM CHLORIDE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; ENCAPSULATING PERITONEAL SCLEROSIS; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONEAL FIBROSIS; PERITONEUM; PRIORITY JOURNAL; RAT; REMISSION; ANIMAL; ARTICLE; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; METHODOLOGY; PATHOLOGY; SCLEROSIS; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; AZATHIOPRINE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; PERITONEAL DIALYSIS; PERITONEAL DISEASES; PERITONEUM; RATS; RATS, WISTAR; SCLEROSIS; TREATMENT OUTCOME;

EID: 67449093841     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902902s42     Document Type: Conference Paper

References (11)

1. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG on behalf of the International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. Perit Dial Int 2000; 20(Suppl 4):S43-55.
2. Lafrance JP, Létourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Mathieu N, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008; 51:e7-10.
3. Kawanishi H, Watanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S39-47.
4. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19:32-5.
5. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005; 25:285-7.
6. Wong CF. Clinical experience with tamoxifen in encapsulating peritoneal sclerosis. Perit Dial Int 2006; 26:183-4.
7. Kawanishi H, Harada Y, Noriyuki T, Kawai T, Takahashi S, Moriishi M, et al. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial 2001; 17:200-4.
8. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187-9.
9. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
10. van Westrhenen R, Aten J, Hajji N, de Boer OJ, Kunne C, de Waart DR, et al. Cyclosporin A induces peritoneal fibrosis and angiogenesis during chronic peritoneal exposure to a glucose-based, lactate-buffered dialysis solution in the rat. Blood Purif 2007; 25:466-72.
11. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619-24.